摘要
目的 观察放疗联合程序死亡受体-1(PD-1)抑制剂及酪氨酸激酶抑制剂(TKI),治疗微卫星稳定(MSS)型或错配修复正常(pMMR)型结直肠癌肝转移(CCLM)的疗效及安全性。方法 回顾性分析江苏省肿瘤医院2021年4月至2023年8月收治的25例MSS型CCLM患者的病历资料。分为观察组(n=12)和对照组(n=13)。观察组给予放疗联合PD-1抑制剂及TKI治疗,对照组给予TKI单药治疗。比较两组患者的基线资料、治疗效果、无进展生存期以及治疗相关不良反应。结果 两组患者的基线资料差异无统计学意义(P> 0.05),观察组的疾病控制率高于对照组(P <0.05),对照组患者的无进展生存期长于观察组,但差异无统计学意义(P> 0.05),两组患者的治疗相关不良事件发生率差异无统计学意义(P> 0.05)。结论 放疗联合PD-1抑制剂及TKI药物的治疗方案与单用TKI对比,提高了MSS型结直肠癌肝转移患者的临床疗效,且未增加不良反应发生率,是一种值得进一步验证的治疗方案。
Objective To observe the efficacy and safety of radiotherapy combined with programmed death receptor⁃1(PD⁃1)inhibitors and tyrosine kinase inhibitors(TKIs)for the treatment of microsatellite⁃stabilized(MSS)⁃type or mismatch⁃matched repair⁃normal(pMMR)⁃type colorectal cancer with liver metastases(CCLM).Methods Case data of 25 patients with MSS⁃type CCLM admitted to Jiangsu Provincial Cancer Hospital from April 2021 to August 2023 were retrospectively analyzed.They were divided into observation group(n=12)and control group(n=13).The observation group was given radiotherapy combined with PD⁃1 inhibitor and TKI treatment,and the control group was given TKI monotherapy.The baseline data,treatment effect,progression⁃free survival,and treatment⁃related adverse reactions of patients in the two groups were compared.Results The difference in baseline data between the two groups was not statistically significant(P>0.05),the disease control rate(DCR)of the observation group was higher than that of the control group(P<0.05),the progression⁃free survival(PFS)of the patients in the observation group was longer than that of the control group,but the difference was not statistically sig⁃nificant(P>0.05),and the difference in the incidence of treatment⁃related adverse events(TRAE)between the two groups was not statistically significant(P>0.05).Conclusion The treatment regimen of radiotherapy com⁃bined with PD⁃1 inhibitors and TKI drugs improved clinical efficacy and did not increase the incidence of adverse events when compared with TKI alone,which is a treatment regimen worthy of further validation.
作者
丁宇轩
郭沥泞
沈佳怡
王丽君
DING Yuxuan;GUO Lining;SHEN Jiayi;WANG Lijun(Affiliated Cancer Hospital of Nanjing Medical University,Nanjing 210009,China;不详)
出处
《实用医学杂志》
CAS
北大核心
2024年第9期1293-1297,共5页
The Journal of Practical Medicine
基金
江苏省卫健委面上项目(编号:M2021093)。
关键词
结直肠癌
放疗
免疫检查点抑制剂
酪氨酸激酶抑制剂
肝转移
colorectal cancer
radiotherapy
immune checkpoint inhibitor
tyrosine kinase inhibi⁃tors
liver metastases
